Picard Medical Inc., the maker of the only total artificial heart approved by both the U.S. FDA and Health Canada, announced the pricing of its initial public offering. The company is offering 4.25 million shares of common stock at $4.00 per share, aiming to raise $17 million in gross proceeds before deducting underwriting fees and other expenses.
The shares of common stock have been approved for listing on the NYSE American, LLC and are expected to commence trading on August 29, 2025, under the ticker symbol PMI.
The company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of common stock at the public offering price, less underwriting discounts, to cover over-allotment, if any.
The company said it plans to use the proceeds from this Offering to support market expansion via a joint venture it has established in China, SynCardia Medical (Beijing), Inc., to fund product research and development activities including those related to the emperor and next-generation portable driver systems; to build STAH system sales, marketing and distribution capabilities, including the costs of additional inventory and an expanded base of drivers, to repay debt, and to cover general operational expenses, working capital and other general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.